Count | |
| 2 | |
| 3 | |
| 1 | |
| 1 | |
Antiparkinson Agents/administration & dosage/blood/*pharmacokinetics | 2 |
Antiparkinson Agents/*administration & dosage/adverse effects | 2 |
| 3 | |
| 1 | |
| 1 | |
| 7 | |
| 13 | |
| 7 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
Antiparkinson Agents/pharmacokinetics/pharmacology/*therapeutic use | 1 |
| 1 | |
| 1 | |
| 3 | |
| 2 | |
Antiparkinson Agents/adverse effects/*pharmacology/therapeutic use | 1 |
Antiparkinson Agents/adverse effects/*pharmacokinetics/*therapeutic use | 1 |
Antiparkinson Agents/adverse effects/pharmacokinetics/*therapeutic use | 1 |
Antiparkinson Agents/*adverse effects/blood/*therapeutic use | 1 |
Antiparkinson Agents/adverse effects/pharmacokinetics/*pharmacology | 1 |
Antiparkinson Agents/adverse effects/*pharmacokinetics/therapeutic use | 1 |
| 1 | |
| 2 | |
| 5 | |
| 30 | |
| 6 | |
| 1 | |
| 1 | |
| 3 | |
| 11 | |
| 2 | |
| 2 | |
| 1 | |
| 1 | |
| 12 | |
| 5 | |
| 2 | |
| 1 | |
| 1 | |
| 10 | |
| 9 | |
| 29 | |
| 26 | |
| 1 | |
| 6 | |
| 6 | |
| 10 | |
| 11 | |
| 2 | |
| 1 | |
| 2 | |
| 1 | |
| 2 | |
| 1 | |
| 2 | |
| 6 | |
| 1 | |
| 1 | |
| 6 | |
| 1 | |
| 1 | |
| 66 | |
| 1 | |
| 1 | |
| 2 | |
| 2 | |
| 3 | |
| 4 | |
| 1 | |
| 14 | |
| 3 | |
| 1 | |
| 1 | |
| 10 | |
| 6 | |
| 58 | |
| 7 | |
| 9 | |